Tissue Regenix has reported interim results for the 6 months to June 2025, noting difficult market conditions affecting revenue performance. Revenues in the period declined 6%, with both divisions reporting falling revenues YoY. BioRinse delivered revenues of $9.8m, down 7% YoY and dCELL reported revenues of $4.0m, down 4% YoY. Gross margin was impacted by the lower volumes, though reduced underlying operating expenses offset the lower gross profit to some extent. Tissue Regenix’s cash balance w ....